Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 15/20 | 0.62 |
| ▸ | MC4R | P32245 | 5/20 | 0.61 |
| ▸ | AKT2 | P31751 | 1/20 | 0.55 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.55 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5331894 | 0.85 | MC4R (0.58) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL14355908 | 0.85 | MC4R (0.58) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL4515320 | 0.82 | MC4R (0.63) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL6157624 | 0.82 | MC4R (0.59) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL5337821 | 0.80 | MC4R (0.64) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL5475767 | 0.80 | MC4R (0.58) | MC4R | |
| SCHEMBL4676286 | 0.78 | MC4R (0.48) | MC4R | |
| SCHEMBL4679456 | 0.78 | MC4R (0.59) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL14355910 | 0.77 | AKT1 (0.61) | AKT1MC4RAKT2AKT1S1AKT3 | |
| SCHEMBL13229901 | 0.77 | AKT1 (1.00) | AKT1AKT2AKT1S1AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | claimed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | claimed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | AKT1 2882/4885MC4R 2/4885AKT2 1873/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | AKT1 2882/4885MC4R 2/4885AKT2 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.